Videos
Strategies for Frontline Follicular Lymphoma Treatment and Curative Potential
10/15/2025
Key Clinical Takeaways
- Design/Population: At the 2025 Lymphoma, Leukemia & Myeloma (LL&M) Congress (New York, NY), Jonathan Friedberg, MD, Wilmot Cancer Institute, reviewed recent clinical trial data in patients with low- and high-tumor–burden follicular lymphoma (FL).
- Key Outcomes: Emerging data demonstrate durable remissions with novel targeted and combination regimens, suggesting potential movement toward functional cure in select FL populations. Ongoing studies are refining sequencing strategies and identifying biomarkers predictive of long-term disease control.
- Clinical Relevance: Advances in FL management—including risk-adapted therapy and novel agents—are improving outcomes across disease stages, with curative intent increasingly feasible for some patients.
At the 2025 Lymphoma, Leukemia & Myeloma (LL&M) Congress in New York, New York, Jonathan Friedberg, MD, Wilmot Cancer Institute, Rochester, New York, reviews recent clinical trial data and shares strategies and insights into the progress made in the treatment and management of follicular lymphoma (FL) for patients with low- or high-tumor burden, highlighting potential towards a curative effect for some patients.
Source:
Friedberg J. How I Approach the Initial Management of Follicular Lymphoma and Can We Talk About Cure? Presented at Lymphoma, Leukemia & Myeloma Congress; October 14-17, 2025. New York, NY.
